Year Founded
2006
Ownership
Private
Employees
~500
Therapeutic Areas
OncologyInfectious Diseases
Stage
Commercial
Modalities
Protein therapeuticsProtein therapeuticsVaccines (general)Adoptive cell therapyDNA-based therapeuticsViral vector gene therapyProtein therapeutics

3P Biopharmaceuticals General Information

A global CDMO formed by the merger of Biovian and 3P Biopharmaceuticals, offering end-to-end development and manufacturing services for biologics

Contact Information

Website
Primary Industry
[ "CRO", "CDMO" ]
Corporate Office
Pamplona-Noáin, Navarra
Spain

Drug Pipeline

No pipeline data available

For full access to 3P Biopharmaceuticals's pipeline data

Book a demo

Key Partnerships

Eleva, Keensight Capital, ERES IV, Sodena

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

3P Biopharmaceuticals Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view 3P Biopharmaceuticals's complete valuation and funding history, request access »

3P Biopharmaceuticals Investors

Keensight Capital
Investor Type: Venture Capital
Holding: Minority
Enisa
Investor Type: Venture Capital
Holding: Minority
Biovian Oy
Investor Type: Venture Capital
Holding: Minority